# A Study to Evaluate the Effect of Umeclidinium (UMEC) as Combination Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT02257372** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 236 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** UMEC DPI
- **DRUG:** Placebo DPI
- **DRUG:** ICS/LABA medication
- **DRUG:** Albuterol/salbutamol Metered Dose Inhaler (MDI)

## Key facts

- **NCT ID:** NCT02257372
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-30
- **Primary completion:** 2015-03-24
- **Final completion:** 2015-03-24
- **Target enrollment:** 236 (ACTUAL)
- **Last updated:** 2017-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02257372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02257372, "A Study to Evaluate the Effect of Umeclidinium (UMEC) as Combination Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02257372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*